hMSCs was obtained by collecting and culturing cancellous bone fragments from a patient undergoing iliac bonegraft. Alendronate (Aln) and Pamidronate (Pam), Ibandronate (Ibn) were added to the culture media in the concentration from 10-3 M to 10-11 M and celltoxicity, viability were measured. For ALP activity evaluation, Aln and Pam were added to the culture media in the concentration from 5x10-7 M to 1x10-8 M and were cultured for 1 week, 2 weeks and 3 weeks. ALP activity data were standardized using protein assay. Control groups were prepared for each examination.
RESULTS:
Aln, Pam and Ibn all failed to increase the proliferation of hMSCs. With 1 week, 2 weeks of 5x10-8 M of Aln treatment, the ALP activity increased. Pam treatment increased the ALP activity with 2 weeks of 5x10-8 M and 1x10-8 M. Also Ibn treatment increased the ALP activity with 2 weeks of 5x10-8 M and 1x10-8 M.
CONCLUSION:
It is considered that BPs are not capable of improving the proliferation of hMSCs. Also, after a transient increase in the ALP activity with the lower concentration of BPs, the activity decreased again. Therefore, in patients on long-term medication of BPs, the proliferation and osteoblast differentiation of hMSCs are restrained, and thus delayed wound healing and increase in BRONJ complications may occur.